Frontiers in Clinical Drug Research - Anti-Cancer Agents: Volume 9 E-Book
55,86 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Wissenschaft und neue Technologien
- Serie: Frontiers in Clinical Drug Research - Anti-Cancer Agents
- Sprache: Englisch
Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. Volume 9 features reviews on these topics:
· Dietary Strategy for Cancer Therapy - Amino Acid Restrictions and Beyond
· The Revolutionary Potential of Noble Metal Nanoparticles as Anti-Cancer Agents: State-of-the-Art Applications and Future Perspectives
· Algal Polysaccharides as Promising Anticancer Agents
· Cardiotoxicity Caused by Doxorubicin and Trastuzumab: Current Understanding for Future Preventive Strategies
· Emodin: Anticancer Agent
Readership
Pharmaceutical Scientists, Medicinal Chemists, Clinical Oncologists, Researchers in Pre-clinical studies and clinical trials.
Das E-Book können Sie in Legimi-Apps oder einer beliebigen App lesen, die das folgende Format unterstützen:
Seitenzahl: 377
Veröffentlichungsjahr: 2024
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
PREFACE
Frontiers in Clinical Drug Research - Anti-Cancer Agents presents recent developments in therapeutic approaches against various types of cancer. This volume is a valuable addition to the series, serving as an important resource for pharmaceutical scientists, postgraduate students, and researchers who seek updated and critical information for devising research plans in anti-cancer research.
The chapters in this volume are written by eminent authorities in the field. Chapter 1, authored by Kang and Li, discusses dietary strategies for cancer therapy, with a focus on amino acid restrictions in cancer interventions. Verma et al., in Chapter 2, elaborate on the role of noble metal nanoparticles (NPs) in creating an effective anti-cancer therapy paradigm, focusing on theranostics and drug delivery mechanisms.
In Chapter 3, Mohamed Gomaa explores the recent anticancer properties of algal polysaccharides from different algal groups and their modes of action. Chattipakorn et al., in the next chapter, summarize current mechanistic insights into the cardiotoxicity of doxorubicin and trastuzumab, addressing the pathophysiology of contractile dysfunction (cardiomyopathy) and electrical disturbances (arrhythmia). Gaps in knowledge and recommendations for future advances are also discussed to encourage further investigations in the field. Finally, in the last chapter of the book, Ahmad et al. comprehensively summarize the anti-proliferative and anti-carcinogenic properties of emodin.
I hope that the readers will find these reviews valuable and thought-provoking, triggering further research in the quest for new and novel therapies against cancers. I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Editorial Director), Mr. Obaid Sadiq (In-charge, Books Department), and Miss Asma Ahmed (Senior Manager, Publications) at Bentham Science Publishers.
List of Contributors
Dietary Strategy for Cancer Therapy - Amino Acid Restrictions and beyond
Shu-Ang Li1,Jian-Sheng Kang1,*Abstract
According to the World Health Organization (WHO) report, cancer is one of the leading causes of death, particularly in developing countries. The malignant proliferation and survival of cancer cells rely on the biosyntheses of proteins, nucleotides, and fatty acids. Accumulating pieces of evidence demonstrate that amino acid restrictions are valuable for cancer interventions. Meanwhile, folk remedies using dietary strategies are abused and lack solid rationale. To clarify what, why, and how the potential strategy is, here, we update and recommend a dietary strategy for cancer therapy: the intermittent dietary lysine restriction with the normal maize (lysine deficiency) as an intermittent staple food for days, weeks, or even months, will be a feasible strategy for cancer intervention. In addition, dietary and immunomodulatory supplements, such as low protein starchy foods, vegetables, fruit, and mushrooms, may serve as supplements to satisfy the daily needs of micronutrients and the plethora of dishes.
